Cargando…
Allosteric SHP2 inhibition increases apoptotic dependency on BCL2 and synergizes with venetoclax in FLT3- and KIT-mutant AML
Mutations in the receptor tyrosine kinases (RTKs) FLT3 and KIT are frequent and associated with poor outcomes in acute myeloid leukemia (AML). Although selective FLT3 inhibitors (FLT3i) are clinically effective, remissions are short-lived due to secondary resistance characterized by acquired mutatio...
Autores principales: | Popescu, Bogdan, Stahlhut, Carlos, Tarver, Theodore C., Wishner, Sydney, Lee, Bianca J., Peretz, Cheryl A.C., Luck, Cuyler, Phojanakong, Paul, Camara Serrano, Juan Antonio, Hongo, Henry, Rivera, Jose M., Xirenayi, Simayijiang, Chukinas, John A., Steri, Veronica, Tasian, Sarah K., Stieglitz, Elliot, Smith, Catherine C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10694768/ https://www.ncbi.nlm.nih.gov/pubmed/37992684 http://dx.doi.org/10.1016/j.xcrm.2023.101290 |
Ejemplares similares
-
Phosphorylation of SHP2 at Tyr62 Enables Acquired Resistance to SHP2 Allosteric Inhibitors in FLT3-ITD–Driven AML
por: Pfeiffer, Anamarija, et al.
Publicado: (2022) -
Hypomethylating agent and venetoclax with FLT3 inhibitor “triplet” therapy in older/unfit patients with FLT3 mutated AML
por: Yilmaz, Musa, et al.
Publicado: (2022) -
Framework humanization optimizes potency of anti-CD72 nanobody CAR-T cells for B-cell malignancies
por: Temple, William C, et al.
Publicado: (2023) -
Rapid and Efficient Response to Gilteritinib and Venetoclax-Based Therapy in Two AML Patients with FLT3-ITD Mutation Unresponsive to Venetoclax Plus Azacitidine
por: Zhang, Lei-Si, et al.
Publicado: (2022) -
AML under the Scope: Current Strategies and Treatment Involving FLT3 Inhibitors and Venetoclax-Based Regimens
por: Milnerowicz, Szymon, et al.
Publicado: (2023)